Skip to content

Evaluation of the effect of oral ritodrine on implantation rate of in vitro fertilization – embryo transfer cycles

Effects of oral ritodrine on infertility treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201301146868N5
Enrollment
200
Registered
2013-03-24
Start date
2013-01-29
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility. Female Infertility

Interventions

Intervention 1: In the intervention group Ritodrine pill 10mg, BID will be administered from the day before embryo transfer and continued for 6 days. Intervention 2: In control group no intervention w
Treatment - Drugs
In the intervention group Ritodrine pill 10mg, BID will be administered from the day before embryo transfer and continued for 6 days.

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: women having a normal uterus assessed with hysterosonography or hysteroscopy; infertility due to factors pipe; infertility due to male factor unexplained. Exclusion criteria: women having a systemic diseases; infertility due to advanced pelvic endometriosis; having endometriomas greater than 2 cm.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
The number and quality of oocytes and embryos, embryo transfer quality and results ßHCG. Timepoint: Two weeks after embryo transfer. Method of measurement: Increased ßHCG.

Primary

MeasureTime frame
Successful implantation. Timepoint: Two weeks after embryo transfer. Method of measurement: Increased hormone levels in the blood ßHCG.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahzad Mehrzad Sadaghiani

Tabriz University of Medical Sciences

sadaghianim@tbzmed.ac.ir; golriz.sobhi1359@yahoo.com; wrhrcenter@gmail.com+98 41 1334 1705

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026